Medicine
Locametz 25 mcg powder for injection
Locametz 25 mcg powder for injection is a prescription medicine containing Gozetotide for intravenous use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Do not freeze. Before radiolabeling, store at 2°C to 25°C (36°F…
Key facts
- Active ingredient (INN)
- Gozetotide
- Brand
- Locametz
- Strength
- 25 mcg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Do not freeze. Before radiolabeling, store at 2°C to 25°C (36°F to 77°F). After radiolabeling, store upright with an appropriate lead shielding to protect from radiation, below 30°C (86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V09I Diagnostic radiopharmaceuticals, subgroup V09I
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 March 2022
- Identifiers
- DailyMed set ID 8683b06e-4901-4526-89ad-23a8fe2d1331NDC 0078-1224Application NDA215841
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, multi-dose in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, multi-dose | 0078-1224-61 | Novartis Pharmaceuticals | 15 January 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Gozetotide
Clinical summary
Gozetotide is a prescription medicine indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer, among other approved uses. MedsAcross supplies Gozetotide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GozetotideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LOCAMETZ prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Locametz: European public assessment report (EPAR) · European Medicines Agency
Need Locametz 25 mcg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.